Braveheart Bio, a clinical-stage biopharmaceutical company focused on treatments for hypertrophic cardiomyopathy (HCM), announced it will participate in the Jefferies Global Healthcare Conference in London from November 16-19, 2026. The company's management will hold a fireside chat on November 18 to discuss their lead drug candidate BHB-1893, a next-generation cardiac myosin inhibitor designed to treat obstructive and non-obstructive HCM. This event offers investors and stakeholders insight into Braveheart Bio's progress in developing therapies addressing serious cardiovascular diseases. A live webcast and replay will be available on the company's website.
Braveheart Bio's upcoming participation in the Jefferies Global Healthcare Conference in London provides context for healthcare sector activity on Pluang. For readers following healthcare stocks, here is Pluang's market snapshot as of Nov 09, 2026 18:41 WIB: out of 150 priced US health-sector stocks, 108 rose and 26 fell today. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 8.99 with a 4.53% increase and a typical hold time of 12 days, Abeona Therapeutics Inc (ABEO) at USD 3.99 down 4.32% with a 28-day hold, and Roivant Sciences Ltd. (ROIV) at USD 40.39 up 3.88% with a 15-day hold.
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
Credit Agricole Toulouse 31 disclosed its weekly transactions involving the buyback of its cooperative investment certificates (CCI) from November 2 to November 6, 2026. The bank repurchased varying volumes daily, with prices ranging around 98.82 to ...
